Introduction
============

*Campylobacter jejuni*, one of the most common causes of bacterial diarrhea worldwide, is biologically distinct from other enteric pathogens, such as *Salmonella*, *Shigella*, and *Vibrio*. A member of the epsilon proteobacteria, *C. jejuni* is more similar to Gram negative mucosal pathogens such as *Haemophilus influenzae* and *Neisseria meningitidis* in that it is microaerophilic, naturally transformable, and encapsulated. The polysaccharide capsule (CPS), which is the topic of this review, is unique for an enteric pathogen, and the *C. jejuni* capsular polysaccharides are unique compared to most others.

*Campylobacter* Capsules: Structures and Genetics
=================================================

During the 1990s, Aspinall and co-workers discovered that *Campylobacter* species (*C. jejuni*, *C. coli*, and *C. lari*) exposed polysaccharides (PSs) that were considered to be O-chain PS regions of cell-wall lipopolysaccharides (LPSs; Aspinall et al., [@B3], [@B4], [@B5],[@B6]; McDonald, [@B56]; Aspinall, [@B2]). However, structural data obtained from some *Campylobacter* species showed that these moieties were not associated with a LPS component, but were of the same type as teichoic acid PSs, as in *C. jejuni* serotype HS1 (for Heat Stable serotype; McDonald, [@B56]) and capsule PSs (CPSs), as in *C. lari* (Aspinall, [@B2]). Subsequently, genomic analysis provided confirmation that the observed PSs of *C. jejuni* were capsule (CPSs; Parkhill et al., [@B74]). Corcoran et al. ([@B16]) demonstrated the phospholipid anchor in three CPS types (HS3, HS6, and HS23/36) was dipalmitoyl-glycerophosphate, with ester-linked hexadecanoic acids. *Campylobacter* species, like other Gram negative mucosal pathogens and unlike other enteric pathogens, express a CPS and lipooligosaccharide (LOS; core → lipid A) in lieu of a full length LPS (O-chain → core → lipid A). The Penner serotyping scheme is a passive slide hemagglutination that is based primarily on CPSs, although other structures, including LOS can contribute to serotype specificity (Penner and Hennessy, [@B77]; Preston and Penner, [@B82]; Karlyshev et al., [@B41]). A total of 23 serotypes were initially described in the original publication (Penner and Hennessy, [@B77]), and this was quickly extended to 47 serotypes for *C. jejuni*, although many are found in related, cross-reacting complexes.

The structure of eight CPS types of *C. jejuni* have been published (Aspinall et al., [@B3], [@B7]; Hannify et al., [@B31]; Muldoon et al., [@B65]; Karlyshev et al., [@B40]; McNally et al., [@B59], [@B60]; Gilbert et al., [@B25]; Chen et al., [@B13]), and these vary in sugar composition and linkage. The expression of (i) heptoses of unusual configuration (i.e., *altro*, *ido*, *gulo*, *talo*) and (ii) *O*-methyl phosphoramidate (MeOPN) are key structural markers of the capsules of *Campylobacter* species, especially *C. jejuni* (Figure [1](#F1){ref-type="fig"}). The structural complexity of the heptoses is further enhanced by the introduction of a deoxy function at the C-6 position, in that, within a single CPS polysaccharide chain, it is common to observe the presence of the heptose and its complementary 6-deoxy-heptose, for example, [d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*altro*-heptose and 6-deoxy-*altro*-heptose in *C. jejuni* strains that belong to serotype complex HS23/36 (Aspinall et al., [@B4]; Kanipes et al., [@B38]). MeOPN has been identified on most *C. jejuni* CPSs, although it is found attached in different linkages to different sugars in each (Karlyshev et al., [@B40]; McNally et al., [@B60]). MeOPN is also found in non-stoichiometric amounts, likely because of phase variation (see below).

![**Covalent structure of the CPS from *C. jejuni* strain 81--176 (serotype HS23/36)**. The trisaccharide repeating block is composed of → 3)-D-Gal*p*-(1 → 2)-3-Me-6d-α-D-altro-Hep*p*-(1 → 3)-β-D-Glc*p*NAc-(1 → . The methylated heptose is sometimes substituted by 6-deoxy-*altro*-heptose. The *O*-methyl phosphoramidate side chain is connected to the C-2 position of Gal in non-stoichiometric amounts (Kanipes et al., [@B38]).](fcimb-02-00007-g001){#F1}

*Campylobacter jejuni* capsules are assembled via an ABC transporter mechanism, similar to class 2 and class 3 capsules of *E. coli* K1 and K5, *N. meningitidis* and *H. influenzae*, and the genetic organization of capsule genes in *C. jejuni* is similar to those found in these bacteria, as shown in Figure [2](#F2){ref-type="fig"}. Capsule genes in these groups are organized in three regions, where the conserved regions 1 and 3 are involved in capsule assembly and transport, and the variable region 2 encodes genes responsible for synthesis of the polysaccharides. The major difference between CPS groups 2 and 3 is the organization of the *kps* genes, and the presence of an additional gene involved in thermoregulation of capsule synthesis, *kpsU*, in group 2 capsule strains. *C. jejuni* is more similar to the group 3 capsules by its absence of the *kpsU* gene and apparent lack of thermoregulation (Stintzi, [@B98]), but appears to be a hybrid between groups 2 and 3 due to differences in gene organization (Figure [2](#F2){ref-type="fig"}). Although the *kpsM* gene of 81--176 has been shown to functionally complement the corresponding mutation in *E. coli* K1 (Bacon et al., [@B9]), no functional studies of *C. jejuni* *kps* gene products have been reported. The function of the products of Class 2 and Class 3 *kps* genes have been reviewed recently (Vimr and Steenbergen, [@B103]).

![**Schematic of the capsule regions of *E. coli* group 2 and group 3 capsules compared to *C. jejuni***.](fcimb-02-00007-g002){#F2}

Region 2, located between *kpsC* and *kpsF* in *C. jejuni*, contains genes that are responsible for biosynthesis of specific polysaccharides (see Figure [3](#F3){ref-type="fig"}). Variability of this region reflects the array of CPS structures/Penner serotypes of *C*. *jejuni*. A total of 18 CPS loci from distinct Penner types have been sequenced to date (Parkhill et al., [@B74]; Pearson et al., [@B76]; Fouts et al., [@B20]; Karlyshev et al., [@B40]; Poly et al., [@B80]). Region 2 in these strains contains from 11 to 30 genes and ranges in size to from 11 to 34 kb. Variation in this region reflects horizontal gene transfer, gene duplication, deletion, and fusion, all of which participate in the observed variability of CPS structures (Karlyshev et al., [@B40]). Despite the high level of overall variability in region 2, some genes are highly conserved. These include genes for synthesis of heptose (*hddC*, *gmhA*, *hddA*) and deoxyheptose (*dmhA*) as well of genes involves in MeOPN biosynthesis. McNally et al. ([@B60]) showed that four genes (CJ1415c--1418c) are required for MeOPN synthesis in NCTC 11168, and these genes are highly conserved in most strains of *C. jejuni*. Two other genes, Cj1419c and Cj1420c, annotated as methyl transferases, are always found adjacent to the MeOPN synthesis genes, although a function has not been ascribed to them. Figure [2](#F2){ref-type="fig"} indicates that 61.5% (8/13) of published CPS loci contain homologs of Cj1415c--Cj1420c. BLAST analysis reveals the presence of these genes not just in *C. jejuni* strains, but also in other epsilon proteobacteria, including other species of *Campylobacter*, *Wolinella succinogenes*, and *Helicobacter* spp. other than *H. pylori*. Production of CPS in those strains in uncertain, but the high degree of protein identity and gene order of the homologs suggests a common source of origin (lateral transfer) of those genes as well as a putative biosynthesis of MeOPN by a wider number of species than originally thought (McNally et al., [@B60]).

![**Schematic of variable region 2 CPS loci from sequenced representative Penner serotype loci**. The function or putative function of genes is color-coded, as indicated.](fcimb-02-00007-g003){#F3}

McNally et al. ([@B60]) also identified two genes adjacent to the MeOPN gene cluster, Cj1421c and Cj1422c, as transferases responsible for addition of MeOPN to two distinct sites in the CPS of an HS2 CPS (the C-3 of β-[d]{.smallcaps}-Gal*f*NAc and to the C-4 of [d]{.smallcaps}-*glycero*-α-[l]{.smallcaps}-*gluco*-heptopyranose residues). Based on similarity to these MeOPN transferases, other putative MeOPN transferases can be identified in additional *C. jejuni* CPS loci, all of which appear to be adjacent to the MeOPN biosynthesis genes. These putative MeOPN transferases contain a conserved N-terminal region sequence and a variable C-terminal region. The conserved region likely encodes the region of the enzyme that recognizes MeOPN, while the variable region likely reflects the different sugar residues to which MeOPN is attached.

The genes encoding enzymes for biosynthesis of heptose and deoxyheptose are also highly conserved in various CPS loci. CPS heptoses are synthesized by the products of *hddC* (putative [d]{.smallcaps}-glycero-[d]{.smallcaps}-manno-heptose 1-phosphate guanosyltransferase), *gmhA2* (phosphoheptose isomerase), *hddA* (putative [d]{.smallcaps}-glycero-[d]{.smallcaps}-manno-heptose 7-phosphate kinase). Biosynthesis of deoxyheptose has been demonstrated in *C. jejuni* (Karlyshev et al., [@B40]) and linked by homology of sequence to *dmhA* a putative GDP-mannose 4,6-dehydratase involves in the conversion of heptose to deoxyheptose. The enzymatic properties of DmhA from strain 81 to 176 were recently characterized (McCallum et al., [@B55]).

Regulation of CPS Expression
============================

The ability of *C. jejuni* to undergo phase variations by slip strand mispairing during replication at homopolymeric tracts of bases is well established (Linton et al., [@B50]; Guerry et al., [@B29]; Hendrixson, [@B32]). *C. jejuni* CPS expression undergoes phase variable changes at two levels. Expression of CPS undergoes an on/off phase variation, likely due to slip strand mismatching in one or more genes in region 1 and 3 (Bacon et al., [@B9]; Guerry and Szymanski, [@B28]). Other phase variations can modulate the CPS structure. Thus, GC tracts are commonly found in *dmhA*, Cj1420c (one of the genes adjacent to the MeOPN genes, see above), as well as putative MeOPN transferases. Thus, phase variable changes in *dmhA* may regulate the amount of deoxyheptoses in the capsules of HS23/36 complex, and changes in the MeOPN transferases are thought to be responsible for the non-stoichiometric amounts of this modification on the CPS.

There is also some evidence that CPS expression is regulated transcriptionally. Experimental determination of the transcriptional patterns of the capsule genes has not been reported, but *in silico* studies by Petersen et al. ([@B79]) suggested a *rpoD* (sigma^70^)-regulated operon that started with *kps*M and extended into region 2. Transcriptional profiling studies have suggested that some of the genes involved in CPS biosynthesis are regulated differentially. Thus, four genes in region 2 were reported to be up-regulated under growth conditions with high iron (Palyada et al., [@B73]), and some CPS genes in both region 2 and region 3 were down regulated *in vivo* in the stomach of pigs (Reid et al., [@B84]). *In vitro* studies showed that four genes involved in CPS transport and three genes involved in polysaccharide biosynthesis were down regulated when *C. jejuni* was grown in the presence of HCT-8 human intestinal epithelial cells (Corcionivoschi et al., [@B15]). The significance of these changes to capsule structure and virulence remain to be determined.

Role of Capsules in Virulence
=============================

The ability to turn CPS expression on and off suggests that CPS expression may be advantageous at some points during the *C. jejuni* lifestyle and disadvantageous at others, suggesting a role in virulence. Similarly, the ability to phase vary the structure of the CPS, such as modifying the levels of MeOPN, likely serves a biological purpose. Polysaccharide capsules are important in virulence for virtually all bacteria that express these structures, but surprisingly little is understood about the role that CPS plays in *C. jejuni*-mediated disease. Bacon et al. ([@B9]) showed that a *kpsM* mutant of strain 81--176 showed a modest (about 10-fold) reduction in invasion of intestinal epithelial cells *in vitro*. Similar results were obtained using non-encapsulated mutants of other strains by Bachtiar et al. ([@B8]) and Corcionivoschi et al. ([@B15]). The latter study also demonstrated that capsule expression by both 81--176 and NCTC 11168 was reduced by passage with HCT-8 intestinal cells in culture, as mentioned above. This result was somewhat unexpected, but the passaged cells showed reduced invasion that correlated with reduced capsule expression. However, the passaged cells represented those not attached to the monolayer; the authors did not examine capsule expression on adhered or invaded cells.

There have been a few studies that have examined the interaction of the *C. jejuni* CPS with various components of the host innate immune response. *C. jejuni* shows levels of resistance to complement killing that are comparable to those of other mucosal pathogens, and, like other mucosal pathogens, the CPS contributes to resistance to complement killing (Bacon et al., [@B9]; Keo et al., [@B42]). However, it is not clear if complement resistance is required for intestinal colonization or after invasion of the intestinal epithelium. Zilbauer et al. ([@B106]) showed that *C. jejuni* 81--176 and NCTC 11168 induced human β-defensins 2 and 3 (hBD2 and hBD3) from intestinal epithelial cells in culture, but that both wildtype and *kpsM* mutants of both strains were equally sensitive to the action of these β-defensins. This is consistent with work of Keo et al. ([@B42]) who showed that the LOS core played a role in resistance to β-defensins and polymyxin, but that the CPS played a limited role. In contrast, capsules on other mucosal pathogens have been shown to protect against β-defensins (Campos et al., [@B11]). Rose et al. ([@B89]) showed that non-encapsulated mutants showed increased production of IL-6, IL-10, and TNF-alpha from murine dendritic cells. A similar effect was seen with mutant that lacked MeOPN on the capsule, suggesting an important biological role for this unusual modification.

There are limited small animal models for *C. jejuni* disease. Champion et al. ([@B12]) have developed a model using the larvae of the wax moth, *Galleria mellonella*. Injection of three different strains of *C. jejuni* into the larvae resulted in rapid killing. Using specific mutants the authors showed that the polysaccharide CPS of strain NCTC 11168, and specifically, the MeOPN modification, was responsible for this lethality. This may be related to the fact the MeOPN is structurally related to organophosphorus pesticides, but the significance of this finding to human disease remains to be determined. Chickens, which can become colonized with *C. jejuni* without disease, have been used to study commensalism. Two groups have shown that encapsulated strains colonize chickens better than unencapsulated mutants (Grant et al., [@B27]; Bachtiar et al., [@B8]). Unfortunately, there are few diarrhea models of disease for *C. jejuni*, but Bacon et al. ([@B9]) showed that a *kpsM* mutant of 81--176 was attenuated in diarrheal disease in an infant ferret model. More convincing evidence of a role in diarrheal disease has come from vaccination studies in non-human primates (see below).

The Burden of *C. jejuni* Disease
=================================

*Campylobacter jejuni* infection, which occurs through exposure to contaminated food and water, is a major global health problem. In the developing world it is estimated that 40--60% of children under the age 5 will develop at least one symptomatic infection, usually occurring during the first year of life (reviewed in Coker et al., [@B14]). Epidemiologic studies are lacking in geographically diverse settings, but those that do exist suggest that repeated pediatric infections are not uncommon. Recent data suggest that *Campylobacter* may be even more important than previously thought. The Global Enterics Multi-Center Study (GEMS), a prospective, multi-center, case--control study of acute diarrhea in children 0--59 months of age funded by the Bill and Melinda Gates Foundation, has found in 2-year follow-up data that *Campylobacter* infections in Asia (Bangladesh, India, Pakistan) represent important enteric infections leading to severe diarrhea in the first years of life (Levine, [@B49]). A recent passive clinical surveillance study in a defined catchment population from Karachi, Pakistan reports an annual incidence of *C. jejuni* infection of 29 per 1,000 person-years, with peak incidence at around 2 years of age (Soofi et al., [@B96]). It is notable that *C. jejuni* infections were more frequently diagnosed than *Shigella*, though *Shigella* was more often associated with dysentery. Additionally, for the developing world, one must consider the association between *Campylobacter* and HIV infection where incidence may be increased, and morbidity and mortality are found to be higher among HIV positive individuals (Sorvillo et al., [@B97]; Molina et al., [@B63]; Tee and Mijch, [@B101]). In a case series of 38 patients with HIV and *Campylobacter* infection, acute diarrhea, fever, and abdominal pain was a predominant symptom complex, however 11% had bacteremia, and 8% experienced chronic diarrhea (Molina et al., [@B63]). Furthermore, long-term carriage of *Campylobacter* can occur, sometimes associated with recurrent attacks of enteritis and bacteremia among HIV infected individuals. Given the growing HIV pandemic, it is estimated that the burden of campylobacteriosis in developing countries may be among the top 10 in 2020.

In the industrialized world, general population incidence estimates based on passive surveillance vary depending on geography and over time with rates in the US averaging around 15/100,000 with a slow decline over the past decade, and rates in Europe around 50--90/100,000 with rising trends (reviewed in Janssen et al., [@B33]). Some countries in Eastern Europe and New Zealand have higher incidence rates of 300--400/100,000 per year. Due to underreporting of these types of illness, true rates of campylobacteriosis are considered to be 10--100 times higher than those reported historically. To this end, recent population-based studies in a number of developed countries have employed varied study designs to estimate overall incidence of *Campylobacter* infections through use of cohort studies, state of the art and standardized identification methods, surveys, and active surveillance networks (Table [1](#T1){ref-type="table"}). These studies confirm the underreporting and case ascertainment bias associated with passive surveillance studies and find that incidence of *Campylobacter* infection ranges from 3 to 15 cases per 1,000 person-years.

###### 

**Global estimates of *Campylobacter* incidence in developed countries**.

  Reference                                             Kubota et al. ([@B44])                                                                                     Tam et al. ([@B99])                                                                                                          De Wit et al. ([@B18])                                                                     Hall et al. ([@B30])                                                                                        Scallan et al. ([@B91])
  ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Country                                               Japan                                                                                                      UK                                                                                                                           Netherlands                                                                                Australia                                                                                                   US
  Year of study                                         2006--2007                                                                                                 2008--2009                                                                                                                   1998--1999                                                                                 2000--2004                                                                                                  2006
  Study design                                          Two 2-week cross-sectional, population-based telephone surveys combined with catchment area surveillance   Prospective, community cohort study and prospective study of general practice presentation in national surveillance system   Prospective population-based study with nested case--control study in general population   Empirical model based on published and unpublished data from multiple active/passive surveillance sources   Empirical model based on published and unpublished data from multiple active/passive surveillance sources
  Numbers                                               4,247 Household interviews, 8,462 laboratory confirmed cases ascertained in active surveillance            6,836 Cohort participants, 800,000 catchment area for national surveillance                                                  4,860 Patients enrolled in cohort                                                          Not applicable                                                                                              Not applicable
  Incidence estimate (95% CI), per 1,000 person-years   15.1 (7.4--28.6)                                                                                           10.9 (7.4--15.9)                                                                                                             4.8 (1.7--10.4)                                                                            11.8 (7.6--26.7)                                                                                            2.8 (not given)
  Foodborne illness rank                                1 of 3 overall                                                                                             4 of 12 overall; 1 of 5 bacterial                                                                                            1 of 5 bacterial                                                                           1 of 3 overall                                                                                              4 of 31 overall; 3 of 21 bacterial

Finally, travelers represent unique populations that are at high risk for *Campylobacter*, where globally it occurs in 5--15% of diarrheal cases (Riddle et al., [@B85]; Shah et al., [@B92]). *Campylobacter* infections are considerably more frequent in some areas of SE Asia. Ravel et al. ([@B83]) recently reported data from an enhanced, passive surveillance system of travel-related diseases caused by enteropathogens within a Canadian community from June 2005 to May 2009. Of the 446 cases of travel-related disease due to enteropathogens reported, *Campylobacter* was the most frequently identified cause (*n* = 123, 28%). Similarly, in a report from the GeoSentinel Travel Network, a clinician-based sentinel surveillance data for 17,353 ill returned travelers, *Campylobacter* was identified in 8.5 per 100 diarrheal cases and was the leading bacterial etiology (Freedman et al., [@B21]).

Taken together, these data highlight the clear importance of *Campylobacter* in global populations in terms of disease incidence, but do not completely portray the enormity of *Campylobacter* as a public health problem. An increasing number of studies are highlighting *Campylobacter*-associated chronic health sequelae (Table [2](#T2){ref-type="table"}). Beyond the well described association with Guillain--Barré Syndrome (GBS), the leading cause of acute flaccid paralysis in the developing world for which up to a third can be attributed to *Campylobacter*, reactive arthritis, inflammatory bowel disease (particularly Crohn's Disease), and irritable bowel syndrome are also recognized as post-campylobacteriosis sequelae in industrialized populations, although there is lack of information on these sequelae in the developing world. Furthermore, it will be of interest to explore possible associations with CPS type as well as other virulent mechanisms and these health sequelae.

###### 

**Summary evidence of post-*Campylobacter* infection risk of select chronic health consequences**.

  Sequelae                     Post-infective attributable risk[\*](#tfn1){ref-type="table-fn"}   Comment                                                                                                                                                                                               Reference
  ---------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  Guillain Barré syndrome      1 per 1,000                                                        14--32% of GBS cases can be attributed to *C. jejuni*                                                                                                                                                 Nachamkin et al. ([@B66])
  Reactive arthritis           1--5%                                                              5% of *C. jejuni* ReA may be chronic or relapsing                                                                                                                                                     Pope et al. ([@B81])
  Inflammatory bowel disease   3--4 per 10,000                                                    Recent evidence suggests that *C. jejuni* can breach the intestinal barrier and may prime the intestine for chronic inflammatory responses in susceptible individuals (Kalischuk and Buret, [@B37])   Gradel et al. ([@B26]), Jess et al. ([@B34]), Rodriguez et al. ([@B88])
  Irritable bowel syndrome     1--10%                                                             IBS developed in 36% of patients associated with a large waterborne outbreak of mixed *Campylobacter* and STEC in Walkerton, Canada. Symptoms persist in approximately 40--50% at 5--7 years          Rodriguez and Ruigomez ([@B87]), Thornley et al. ([@B102]), Dunlop et al. ([@B19]), Marshall et al. ([@B53])

*\*Post-infective attributable risk considers the absolute difference of the rate of sequelae after *C. jejuni* compared to the rate of the sequelae in an unexposed population*.

From a public health perspective, some country-level approaches have been attempted to quantify and characterize the burden and cost associated with acute diarrheal infections and their chronic consequences. For example, in New Zealand it is estimated that major foodborne illness and its chronic health consequences costs society approximately \$86 million per year, and 90% of this cost is attributed to lost productivity due to absence from work (Lake et al., [@B45]), and campylobacteriosis is shown to account for approximately 90% of the estimated cost of foodborne illness. Cost and burden of disease studies in Australia and the Netherlands have also been conducted outlining substantial individual and societal costs in which acute disease is either matched or exceeded by the chronic consequences (Mangen et al., [@B52]). Beyond the country-level perspective focusing on domestically acquired foodborne infections, populations at high risk for acute infectious diarrhea (e.g., travelers, military) should also be considered in estimating the full burden of disease and the potential value of current and novel interventions. It should be noted, while not as well studied, the chronic consequences of *Campylobacter* infections in developing world populations should not be under-estimated. Given the known mucosal barrier disruption effects of *Campylobacter* infection (Beltinger et al., [@B10]), the contribution of this particular infection may emerge as an important factor to malnutrition and associated consequences in the developing world. An international group of investigators are collaborating on a project entitled The Interactions of Malnutrition and Enteric Infections (MAL--ED): Consequences for Child Health and Development (<http://mal-ed.fnih.org/>), involving a network of eight sites that are exploring the factors associated with a child's risk of enteric infection, chronic diarrhea, malnutrition, as well with impaired gut function, vaccine response, and cognitive and physical development (Lorntz et al., [@B51]; Tarleton et al., [@B100]; Santos et al., [@B90]; Oria et al., [@B70]). Given the known mucosal barrier disruption effects of *Campylobacter* infection, it will be important to follow.

While more study utilizing improved diagnostics and characterizing the pathogenesis of acute and chronic health effects of *Campylobacter* infections is needed, the data that is available suggest that control of *Campylobacter* should be considered a global public health priority. Promotion and strengthening of food safety systems, good manufacturing practices and educating retailers and consumers about appropriate food handling and avoiding contamination are needed now and can be employed. Education of consumers and training of food handlers in safe food handling is one of the most critical interventions in the prevention of foodborne illnesses. Due to the challenges of implementing these aforementioned strategies, however, vaccines for use in travelers, military personnel, and pediatric populations in the developing world are much needed. To this end, we have explored the feasibility of CPS conjugate vaccines against *C. jejuni*.

CPS Conjugate Vaccines as a Strategy Against *C. jejuni*
========================================================

CPS-based vaccine strategies have been very successful at reducing the overall disease incidence of several encapsulated bacteria including *Streptococcus pneumoniae, N. meningitidis*, and *H. influenzae* (reviewed in Lesinski and Westernick, [@B47]; Knuf et al., [@B43]). Given the success of these capsular-based vaccines, we have begun studies to determine the feasibility of a capsule conjugate vaccine approach to prevent disease caused by *C. jejuni*.

Most capsular polysaccharides are thymus-independent (TI) antigens meaning that helper T cells are needed to generate robust, long-lived antibody responses. Although adults can generate some antibody responses to purified capsules administered as a vaccine (Lesinski and Westernick, [@B48]), children \<2 years of age do not develop strong responses to TI antigens (Rijkers et al., [@B86]). As most carbohydrate antigens cannot directly activate naïve T cells, a carrier protein is often included to optimize immune responses (Knuf et al., [@B43]). This vaccine strategy effectively converts a TI antigen into a thymus dependent (TD) antigen that allows boosting of the immune response, IgG antibody class switching, and the generation of memory cells possessing antibody with higher avidity for CPS (Lesinski and Westernick, [@B48]).

In the initial studies, CPS was purified from *C. jejuni* strains 81--176 (HS23/36) and CG8486 (HS4 complex) and conjugated to the carrier protein, CRM~197~, which is a mutant diphtheria toxin subunit, using reductive amination (Monteiro et al., [@B64]). BALB/c mice were immunized subcutaneously with escalating doses of *C. jejuni* CPS--CRM~197~. Maximal titers were generated following three doses of vaccine. One month after the last dose of vaccine, immunized mice were challenged with each respective strain using an intranasal infection model to determine if vaccination conferred protection. Immunized mice exhibited significantly lower levels of sickness following challenge suggesting that antibodies generated against the capsule afforded some protection against infection with *C. jejuni* in this model. However, testing in a more relevant model was still required.

The New World monkey, *Aotus nancymaae*, has been shown to develop diarrheal disease that mimics aspects of human illness following orogastric challenge with *C. jejuni* (Jones et al., [@B36]). To determine if immunization with CPS--CRM~197~ could prevent diarrheal disease, monkeys were immunized with 2.5 μg of polysaccharide adjuvanted with alum three times with an interval of 6 weeks between subcutaneous injections. Nine weeks following the third immunization, monkeys were challenge orogastrically with approximately 10^11^ CFU of *C. jejuni* 81--176. The diarrheal attack rate for non-immunized control monkeys was 70%. However, 100% of vaccinated animals (14/14) were protected against diarrheal disease (Monteiro et al., [@B64]). This work was the first demonstration that a capsule conjugate vaccine could protect against enteric disease and also suggests that the capsule plays a critical role in virulence.

These proof-of-concept studies proved the feasibility of using a capsule conjugate vaccine to prevent illness caused by *C. jejuni*. However, before developing a vaccine for practical use, the number of CPS types needed to achieve broad coverage against the most prevalent strains of *C. jejuni* needs to be determined

CPS Typing by Multiplex PCR
===========================

The likely target population for a vaccine against *C. jejuni* would be civilian and military travelers to endemic regions and pediatric populations living in endemic areas. However, while there are extensive data on Penner types of *C. jejuni* strains from the developed world, particularly the Europe and Canada, there are limited data from less developed countries (LDC) where the incidence of *C. jejuni* diarrhea is high. Figure [4](#F4){ref-type="fig"} summarizes published data on Penner types from sporadic clinical cases based on \>16,000 clinical isolates from the developed world and about 700 from LDC. A non-systemic review of Penner typing for sporadic clinical cases identified HS4, HS2, and HS1 as the most common globally. The HS4 complex was the most prevalent, accounting for 21.2 and 13.2% of all cases for the developed and LDC, respectively, followed by HS2 (16.4 and 7.96% for developed and LDC, respectively) and the HS1 complex (10.7 and 6.81% for developed and LDC, respectively). Penner types HS3, HS5, and HS8 were also prevalent worldwide, while other serotypes tend to show geographic and population-based variability. More than 10% of isolates from the developed world and \>21% from the developing world were non-typeable in the Penner scheme. This could reflect the existence of CPS types not covered in the Penner typing scheme, but it is also in partly due to the fact that Penner serotyping requires CPS expression and a certain percentage of these isolates have turned capsule expression off by phase variation (Poly, unpublished).

![**Penner serotype distribution worldwide**. The data represent a total of \>16,000 strains from developed countries (Penner and Hennessy, [@B77]; McMyne et al., [@B58]; Penner et al., [@B78]; Jones et al., [@B35]; Patton et al., [@B75]; Mills et al., [@B62]; Albert et al., [@B1]; Skirrow et al., [@B95]; Marshall et al., [@B54]; Owen et al., [@B71]; Nielsen et al., [@B68], [@B69]; Frost et al., [@B22]; McKay et al., [@B57]; Oza et al., [@B72]; Wareing et al., [@B104]; Woodward and Rodgers, [@B105]; Karenlampi et al., [@B39]; Siemer et al., [@B93]; Cornelius et al., [@B17]; Fussing et al., [@B23]; McTavish et al., [@B61]); and far fewer strains (711) from less developed countries, including Central Africa (Georges-Courbot et al., [@B24]), South Africa (Lastovica et al., [@B46]), South Africa (Lastovica et al., [@B46]), Egypt (Poly et al., [@B80]), Bangladesh (Neogi and Shahid, [@B67]), Kuwait (Sjogren et al., [@B94]), and Thailand (Poly et al., [@B80]).](fcimb-02-00007-g004){#F4}

To overcome the limited data on CPS distribution in LDC's, a *C. jejuni* CPS multiplex-based PCR was recently developed and validated. The current CPS multiplex is composed of a total of 14 primer pairs, separated into two mixes, alpha and beta (Poly et al., [@B80]). Primers were designed on specific sequences of available *C. jejuni* class 2 loci (Figure [2](#F2){ref-type="fig"}). Most of the Penner serotypes that fall into related complexes are recognized with the same pair of primers. Thus, the multiplex system does not distinguish between HS23 and HS36 and other similar complexes of Penner types, which have very similar CPS structures that crossreact immunologically. Attribution of CPS type is deciphered based on the length of the PCR product after electrophoresis on a 2% agarose gel along with a molecular weight ladder. This technology was validated on a total of 244 strains of known serotype and shown to have sensitivities and specificities ranging from 90 to 100%. A perfect correlation between CPS type and Penner type was demonstrated. This technology is still expanding and is currently being evaluated in multiple laboratories worldwide. One advantage of the multiplex system over classical serotyping is that the multiplex is independent of phase variation in capsule expression. Collection of additional data by the multiplex PCR will provide a more accurate picture of *C. jejuni* CPS distribution, particularly in LDCs, that will dictate the final formulation of an effective CPS conjugate vaccine. The ability to rapidly determine capsule type will also facilitate studies to determine if specific CPS types are associated with more severe acute diarrheal disease and with the chronic sequelae, particularly functional bowel disorders.
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